利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

9 条记录 (耗时 0.023 秒)

    SUBSTITUTED HETEROCYCLIC COMPOUNDS AND METHODS OF USE
    3.
    发明公开
    SUBSTITUTED HETEROCYCLIC COMPOUNDS AND METHODS OF USE 有权
    取代的杂环化合物和使用方法

    公开(公告)号：EP1664053A1

    公开(公告)日：2006-06-07

    申请号：EP04783482.5

    申请日：2004-08-23

    申请人： AMGEN INC.

    发明人： NUNES, Joseph J. ,  ZHU, Xiaotian ,  ERMANN, Monika ,  GHIRON, Chiara ,  JOHNSTON, David N. ,  SALUSTE, Carl-Gustaf Pierre

    IPC分类号： C07D487/14 ,  A61K31/519

    CPC分类号： C07D487/14

    摘要： The present invention relates to tetracyclic pyrimidines or pyridines or pharmaceutically-acceptable salts or derivatives thereof. Also included are methods of use of the tetracyclic pyrimidines or pyridines including use related to treating inflammation, inhibiting T cell activation and proliferation, arthritis, organ transplant, ischemic or reperfusion injury, myocardial infarction, stroke, multiple sclerosis, inflammatory bowel disease and many other related disorders in a subject, the methods comprising administering a therapeutically-effective amount a compound as described above to the subject.

    摘要翻译： 本发明涉及四环嘧啶或吡啶或其药学上可接受的盐或衍生物。 还包括使用四环嘧啶或吡啶的方法，包括与治疗炎症，抑制T细胞活化和增殖，关节炎，器官移植，局部缺血或再灌注损伤，心肌梗塞，中风，多发性硬化症，炎症性肠病等有关的用途 所述方法包括向所述受试者施用治疗有效量的如上所述的化合物。

    2-AMINO-4-HYDROXY-5-PYRIMIDINCARBOXAMID DERIVATIVES AND RELATED COMPOUNDS AS T-CELL ACTIVATION INHIBITORS FOR THE TREATMENT OF INFLAMMATIONS
    9.
    发明公开
    2-AMINO-4-HYDROXY-5-PYRIMIDINCARBOXAMID DERIVATIVES AND RELATED COMPOUNDS AS T-CELL ACTIVATION INHIBITORS FOR THE TREATMENT OF INFLAMMATIONS 审中-公开
    2-氨基-4-羟基-5-嘧啶甲酰胺衍生物和相关化合物作为T细胞活化的炎症性疾病治疗的抑制剂

    公开(公告)号：EP1648464A1

    公开(公告)日：2006-04-26

    申请号：EP04777011.0

    申请日：2004-06-24

    申请人： AMGEN INC.

    发明人： NUNES, Joseph J. ,  ZHU, Xiaotian ,  AMOUZEGH, Patricia ,  GHIRON, Chiara ,  JOHNSTON, David N. ,  POWER, Eoin Christopher

    IPC分类号： A61K31/506 ,  A61K31/505 ,  C07D239/46 ,  C07D239/48

    CPC分类号： C07D213/82 ,  C07D239/47 ,  C07D239/48

    摘要： The present invention relates to pyrimidine or pyridine carboxamides or pharmaceutically-acceptable salts thereof. Also included is a method of treatment of inflammation, inhibition of T cell activation and proliferation, arthritis, rheumatoid arthritis, psoriatic arthritis, osteoarthritis, organ transplant, acute transplant or heterograft or homograft rejection, transplantation tolerance induction, ischemic or reperfusion injury, myocardial infarction, stroke, multiple sclerosis, inflammatory bowel disease, including ulcerative colitis, Crohn's disease, lupus, contact hypersensitivity, delayed-type hypersensitivity, and gluten-sensitive enteropathy, type 1 diabetes, psoriasis, contact dermatitis, Hashimoto's thyroiditis, Sjogren's syndrome, autoimmune hyperthyroidism, Addison's disease, autoimmune polyglandular disease, autoimmune alopecia, pernicious anemia, vitiligo, autoimmune hypopituatarism, Guillain-Barre syndrome, glomerulonephritis, serum sickness, uticaria, allergic diseases, asthma, hayfever, allergic rhinitis, scleracielma, mycosis fungoides, dermatomyositis, alopecia areata, chronic actinic dermatitis, eczema, Behcet's disease, Pustulosis palmoplanteris, Pyoderma gangrenum, Sezary's syndrome, atopic dermatitis, systemic schlerosis, morphea, atopic dermatitis, colon carcinoma or thymoma in a mammal comprising administering a therapeutically-effective amount a compound as described above.